Goldman Sachs raises target for Moderna stock from USD 120 to USD 137

Published on 10/16/2026 at 09:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ESMO melanoma data are due October 24, 2026. Moderna stock costs EUR 211.25 on October 16, 2026, with USD 94.4 billion market value.

Analyst target and cancer data

Goldman Sachs raised its Moderna target from USD 120.00 to USD 137.00 on October 15, 2026.
Second-quarter revenue reached USD 145.0 million while GAAP net loss was USD 782.0 million on July 31, 2026.
Moderna stock trades at EUR 211.25 at 9:06 a.m. CEST at Lang & Schwarz on October 16, 2026.
Moderna will present melanoma data on October 24, 2026.

Aquarellmalerei der Cambridge-Skyline mit modernen Forschungsgebäuden am Charles River — Moderna Inc. (US60770K1034) präsentiert eine stimmungsvolle Aquarell-Ansicht der Cambridge-Skyline mit modernen Biotech-Forschungsgebäuden am Flussufer, Illustration mit AI erstellt.

Moderna, Inc. (US60770K1079) was trading at EUR 211.25 at Lang & Schwarz at 9:06 a.m. CEST on October 16, 2026. The immediate catalyst is Goldman Sachs raising its price target from USD 120.00 to USD 137.00 while keeping a Neutral rating, according to Markets Insider on October 15, 2026.

Target rises before melanoma data

The analyst view is tied to Moderna's Phase 3 intismeran melanoma results at the European Society for Medical Oncology Congress. Markets Insider reported that a recurrence-free survival hazard ratio below 0.70 is viewed as necessary to support the current share level. The company also has early pancreatic cancer safety and immune-response data ahead.

Three events shaped the stock

On June 1, 2026, Moderna and Merck presented five-year melanoma data showing a 49 percent reduction in the risk of recurrence or death versus Keytruda alone, according to Moderna. On July 31, 2026, second-quarter revenue reached USD 145.0 million and GAAP net loss was USD 782.0 million. On October 15, 2026, Goldman Sachs lifted its target to USD 137.00 from USD 120.00.

What dates matter next?

Moderna's next two scheduled milestones are the October 24, 2026 investor event with melanoma data and the November 6, 2026 release of third-quarter 2026 financial results. The dates come from Moderna.

Revenue remains a key test

The second-quarter loss of USD 782.0 million against USD 145.0 million of revenue leaves the oncology readout carrying significant valuation weight. The November report will show whether operating results are beginning to support the market's much higher assessment.

Moderna was trading at EUR 211.25 at Lang & Schwarz on October 16, 2026 at 9:06 a.m. CEST. The company is listed on Nasdaq under MRNA, where CNBC reported a 52-week range of USD 22.28 to USD 227.46 and a market capitalization of USD 86.3 billion as of October 12, 2026.

The further course of trading is shown by the continuously updated real-time quote of Moderna stock.